JP MORGAN/CALL/MODERNA/120/0.1/20.09.24 | Market Closed - Bid/Ask 19:01:38 05/07/2024 BST | ||
| 1.03 EUR | -6.36% |
|
| Current month | -2.65% | ||
| 1 month | -63.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.03 | -6.36% |
| 04/07/24 | 1.1 | +13.40% |
| 03/07/24 | 0.97 | -5.83% |
| 02/07/24 | 1.03 | +0.98% |
| 01/07/24 | 1.02 | -9.73% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:01 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JB9NSD |
| ISIN | DE000JB9NSD7 |
| Date issued | 09/01/2024 |
| Strike | 120 $ |
| Maturity | 20/09/2024 (77 Days) |
| Parity | 10 : 1 |
| Emission price | 1.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.98 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.01 € |
| Spread % | 0.98% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
